This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Looking into the data behind the FDA approval for Vyvgart Hytrulo (efgartigimod) in patients with generalized Myasthenia Gravis.

Ticker(s): ARGX

Who's the expert?

Institution: University of Buffalo

  • Clinical Associate Professor of Neurology at the University of Buffalo.
  • Research is focused on several studies that address illnesses such as Guillain-Barre syndrome, myasthenia gravis and polyneuropathy.
  • Basic science research is focused on pathophysiology of inherited neuropathies, which are known collectively as Charcot-Marie-Tooth (CMT) disease, with the goal of better understanding the underlying cause or mechanisms of these diseases.

Interview Goal
To discuss the standard of care and the potential of Vyvgart Hytrulo (efgartigimod), a recently approved injectable formulation of efgartigimod developed by Argenx for the treatment of myasthenia gravis.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.